Protagonist Therapeutics Inc (PTGX)
Profitability ratios
Return on sales
| Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross profit margin | 87.37% | 44.31% | -25,973.98% | -25,355.28% | -2,937.58% | -18.85% | 8.10% | 28.09% | 27.50% | -30.20% | -60.35% | -83.36% | -67.15% | -71.04% | -48.80% | -92.15% | -163.62% | -169.43% | -194.36% | -9.32% |
| Operating profit margin | 47.19% | -155.73% | -124,566.67% | -119,669.92% | -14,896.44% | -491.96% | -374.42% | -293.35% | -262.05% | -459.62% | -442.49% | -300.32% | -221.41% | -225.98% | -245.29% | -574.26% | -1,335.36% | -1,863.48% | -1,988.22% | -704.96% |
| Pretax margin | 52.50% | -131.29% | -114,214.63% | -111,878.86% | -14,275.76% | -477.06% | -369.40% | -291.56% | -261.09% | -458.55% | -441.96% | -300.27% | -221.73% | -227.14% | -243.80% | -566.11% | -1,308.27% | -1,801.67% | -1,918.31% | -677.47% |
| Net profit margin | 51.45% | -131.29% | -114,214.63% | -111,878.86% | -14,275.76% | -477.06% | -369.40% | -291.56% | -261.09% | -458.55% | -441.96% | -300.27% | -225.36% | -231.71% | -252.22% | -582.44% | -1,297.82% | -1,786.32% | -1,859.70% | -655.43% |
Protagonist Therapeutics Inc's profitability ratios exhibit significant fluctuations over the past few quarters. The gross profit margin has varied widely, reaching as high as 87.37% in the most recent quarter, reflecting strong control over production costs. However, negative margins in previous periods indicate challenges in managing direct costs efficiently.
The operating profit margin has been highly volatile, with drastic negative percentages in several quarters, pointing towards significant operating losses. This suggests operational inefficiencies or cost structures that have not been sustainable for the company.
Similarly, the pretax margin and net profit margin have displayed extreme fluctuations, with several quarters showing astronomical negative percentages, indicating substantial losses compared to revenue. This highlights persistent challenges in generating profits after accounting for operating and non-operating expenses.
In summary, Protagonist Therapeutics Inc's profitability ratios demonstrate inconsistency and a lack of stable profitability, suggesting the need for strategic and operational improvements to achieve sustainable financial performance in the future.
Return on investment
| Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating return on assets (Operating ROA) | 23.63% | -26.16% | -46.43% | -45.93% | -60.99% | -52.99% | -46.73% | -42.99% | -35.30% | -36.19% | -28.85% | -20.16% | -23.10% | -19.88% | -28.98% | -32.17% | -63.43% | -51.98% | -50.85% | -47.84% |
| Return on assets (ROA) | 25.76% | -22.06% | -42.57% | -42.94% | -58.45% | -51.38% | -46.11% | -42.73% | -35.17% | -36.11% | -28.81% | -20.16% | -23.51% | -20.39% | -29.80% | -32.63% | -61.65% | -49.82% | -47.57% | -44.48% |
| Return on total capital | 26.53% | -27.82% | -50.71% | -50.05% | -67.67% | -60.93% | -54.13% | -49.82% | -40.74% | -41.95% | -32.64% | -22.77% | -26.46% | -22.98% | -37.02% | -43.11% | -136.49% | -100.70% | -82.46% | -84.04% |
| Return on equity (ROE) | 28.93% | -23.45% | -46.49% | -46.80% | -64.85% | -59.09% | -53.41% | -49.51% | -40.59% | -41.85% | -32.62% | -22.80% | -27.02% | -23.66% | -38.19% | -43.83% | -132.71% | -96.53% | -77.13% | -78.13% |
Protagonist Therapeutics Inc's profitability ratios have shown significant fluctuations over the periods analyzed.
- Operating return on assets (Operating ROA) improved significantly from negative percentages in the earlier periods to positive percentages in more recent quarters. This indicates that the company has been able to generate operating income more efficiently from its assets.
- Return on assets (ROA) also displayed a generally improving trend, with negative values transforming into positive percentages in the latest quarters. This suggests that the company has been able to generate profits from its assets, improving its overall asset utilization efficiency.
- Return on total capital exhibited a similar pattern of improvement over time, moving from negative values to positive percentages in recent periods. This metric reflects the company's ability to generate returns from both debt and equity financing.
- Return on equity (ROE) showed a trend of enhancement, with negative percentages converting into positive figures in the most recent quarters. This signifies that the company has been more successful in generating profits from shareholders' equity, reflecting improved financial performance and shareholder value creation.
Overall, the improving trend in these profitability ratios suggests positive developments in Protagonist Therapeutics Inc's operational efficiency and financial performance, potentially indicating better prospects for the company's profitability in the future.